Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients
International Journal of Cancer, 05/03/2012
Widenmeyer M et al. – The HLA–DR restricted epitope is broadly immunogenic and should be valuable for stimulating T helper cells in patients suffering from a wide range of tumors.



